[Clinical study of anti-leukotriene therapy with montelukast in bronchial asthma patients].
Clinical and functional efficacy of the antileukotriene agent montelucast (singulair) was investigated in 30 patients with moderately severe bronchial asthma. Patients with a positive FEV1 response to montelukast (61.1%) demonstrated a higher blood level of IgE and sputum eosinophilia. Enhancement of bronchodilatatory effect secondary to the use of beta 2-agonist has been recordable in the wake of a 24-day montelucast treatment (10 mg o.d.).
Tovt-Korshyns'ka
M I
MI
Spivak
M Ia
MIa
Chopei
I V
IV
Lemko
I S
IS
Kopynets'
I I
II
Il'ina
V O
VO
Kazankevych
V P
VP
Melega
O O
OO
D000085:Acetates / Q000008:administration & dosage / Q000627:therapeutic use*; D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D001249:Asthma / Q000188:drug therapy*; D002648:Child; D003521:Cyclopropanes; D004334:Drug Administration Schedule; D004802:Eosinophilia / Q000139:chemically induced; D005260:Female; D006801:Humans; D007073:Immunoglobulin E / Q000097:blood / Q000187:drug effects; D020024:Leukotriene Antagonists / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011804:Quinolines / Q000008:administration & dosage / Q000627:therapeutic use*; D013183:Sputum / Q000166:cytology / Q000187:drug effects; D013440:Sulfides
D000085:Acetates; D003521:Cyclopropanes; D020024:Leukotriene Antagonists; D011804:Quinolines; D013440:Sulfides; D007073:Immunoglobulin E; C093875:montelukast